# Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

> **NCT00998335** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 30 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Long-acting bedtime insulin detemir (Levemir)
- **DRUG:** Insulin detemir and pre-meal insulin aspart.

## Key facts

- **NCT ID:** NCT00998335
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00998335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00998335, "Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00998335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*